EP0722449A1 - Boropeptid thrombin-inhibitoren, welche einen substituierten pyrrolidinring enthalten - Google Patents
Boropeptid thrombin-inhibitoren, welche einen substituierten pyrrolidinring enthaltenInfo
- Publication number
- EP0722449A1 EP0722449A1 EP94929943A EP94929943A EP0722449A1 EP 0722449 A1 EP0722449 A1 EP 0722449A1 EP 94929943 A EP94929943 A EP 94929943A EP 94929943 A EP94929943 A EP 94929943A EP 0722449 A1 EP0722449 A1 EP 0722449A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- formula
- methyl
- group
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000190 Thrombin Proteins 0.000 title abstract description 21
- 229960004072 thrombin Drugs 0.000 title abstract description 21
- 239000003112 inhibitor Substances 0.000 title abstract description 13
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 229940002612 prodrug Drugs 0.000 claims abstract description 12
- 239000000651 prodrug Substances 0.000 claims abstract description 12
- -1 cyclic boron ester Chemical class 0.000 claims description 169
- 150000001875 compounds Chemical class 0.000 claims description 146
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 77
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 40
- 229910052760 oxygen Inorganic materials 0.000 claims description 40
- 239000001301 oxygen Substances 0.000 claims description 39
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 38
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 239000001257 hydrogen Substances 0.000 claims description 31
- 229910052717 sulfur Inorganic materials 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 18
- 125000005842 heteroatom Chemical group 0.000 claims description 18
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 229910052796 boron Inorganic materials 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 108010022999 Serine Proteases Proteins 0.000 claims description 8
- 102000012479 Serine Proteases Human genes 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 6
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 6
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 150000001721 carbon Chemical group 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 239000011593 sulfur Substances 0.000 claims description 5
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 claims description 4
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims description 4
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 4
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 3
- 235000010290 biphenyl Nutrition 0.000 claims description 3
- 239000004305 biphenyl Substances 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims description 2
- 125000004173 1-benzimidazolyl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N1* 0.000 claims description 2
- PHRABVHYUHIYGY-UHFFFAOYSA-N 1-methylnaphthalene Chemical group C1=CC=C2C([CH2])=CC=CC2=C1 PHRABVHYUHIYGY-UHFFFAOYSA-N 0.000 claims description 2
- 125000006345 2,2,2-trifluoroethoxymethyl group Chemical group [H]C([H])(*)OC([H])([H])C(F)(F)F 0.000 claims description 2
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 claims description 2
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 claims description 2
- 229930194542 Keto Natural products 0.000 claims description 2
- 229910018828 PO3H2 Inorganic materials 0.000 claims description 2
- 229910006095 SO2F Inorganic materials 0.000 claims description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000468 ketone group Chemical group 0.000 claims description 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims description 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 2
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims description 2
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims description 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 2
- 125000004001 thioalkyl group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 1
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 claims 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 abstract description 4
- 235000008206 alpha-amino acids Nutrition 0.000 abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- 239000002585 base Substances 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 25
- 239000000243 solution Substances 0.000 description 22
- 239000000047 product Substances 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- 230000002829 reductive effect Effects 0.000 description 19
- 239000000203 mixture Substances 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 150000001412 amines Chemical class 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 229940122388 Thrombin inhibitor Drugs 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 239000003868 thrombin inhibitor Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 235000013930 proline Nutrition 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 150000001540 azides Chemical class 0.000 description 7
- 150000002431 hydrogen Chemical class 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 230000015271 coagulation Effects 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 238000006073 displacement reaction Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical group NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 150000003148 prolines Chemical class 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KKWSSPUIRYKIAT-UHFFFAOYSA-N 1-aminopentylboronic acid Chemical compound CCCCC(N)B(O)O KKWSSPUIRYKIAT-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000002965 anti-thrombogenic effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 3
- 229940077388 benzenesulfonate Drugs 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 3
- 229940092714 benzenesulfonic acid Drugs 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000020764 fibrinolysis Effects 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 238000005809 transesterification reaction Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 241000237902 Hirudo medicinalis Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000006242 amine protecting group Chemical group 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 125000005620 boronic acid group Chemical class 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 229960003766 thrombin (human) Drugs 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 125000005270 trialkylamine group Chemical group 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- YDMBNDUHUNWWRP-VJBWXMMDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]piperidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C1=CC=CC=C1 YDMBNDUHUNWWRP-VJBWXMMDSA-N 0.000 description 1
- MVTHUEOHHHQQKY-QMMMGPOBSA-N (2s)-2-(diaminomethylideneamino)-3-phenylpropanoic acid Chemical class NC(N)=N[C@H](C(O)=O)CC1=CC=CC=C1 MVTHUEOHHHQQKY-QMMMGPOBSA-N 0.000 description 1
- WNCIWSMKRPFIJY-BTAJCFKJSA-N (2s)-2-[[(2s,3s)-2-[[(2s)-1-[(2s)-5-(diaminomethylideneamino)-2-[(2,5-dihydroxybenzoyl)amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]butanoic acid Chemical compound CC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)C1=CC(O)=CC=C1O WNCIWSMKRPFIJY-BTAJCFKJSA-N 0.000 description 1
- KHZVLGLEHBZEPO-QMMMGPOBSA-N (2s)-2-hydrazinyl-3-phenylpropanoic acid Chemical class NN[C@H](C(O)=O)CC1=CC=CC=C1 KHZVLGLEHBZEPO-QMMMGPOBSA-N 0.000 description 1
- SHINASQYHDCLEU-BKLSDQPFSA-N (2s)-4-aminopyrrolidine-2-carboxylic acid Chemical group NC1CN[C@H](C(O)=O)C1 SHINASQYHDCLEU-BKLSDQPFSA-N 0.000 description 1
- OYNANFOWNSGDJL-BKLSDQPFSA-N (2s)-4-sulfanylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CC(S)CN1 OYNANFOWNSGDJL-BKLSDQPFSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- JHDMMNYIVVWNOF-UHFFFAOYSA-N 1,2-dicyclohexylethane-1,1-diol Chemical compound C1CCCCC1C(O)(O)CC1CCCCC1 JHDMMNYIVVWNOF-UHFFFAOYSA-N 0.000 description 1
- SUNMBRGCANLOEG-UHFFFAOYSA-N 1,3-dichloroacetone Chemical class ClCC(=O)CCl SUNMBRGCANLOEG-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- XNKQYQOTERJNHJ-YUMQZZPRSA-N 1-o-tert-butyl 2-o-methyl (2s,4s)-4-chloropyrrolidine-1,2-dicarboxylate Chemical compound COC(=O)[C@@H]1C[C@H](Cl)CN1C(=O)OC(C)(C)C XNKQYQOTERJNHJ-YUMQZZPRSA-N 0.000 description 1
- OBGFNGZXMSFPAR-UHFFFAOYSA-N 2,5-dimethylhexane-3,3-diol Chemical compound CC(C)CC(O)(O)C(C)C OBGFNGZXMSFPAR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- OTVHXWFANORBAK-UHFFFAOYSA-N 3-(1h-indol-3-yl)propanamide Chemical compound C1=CC=C2C(CCC(=O)N)=CNC2=C1 OTVHXWFANORBAK-UHFFFAOYSA-N 0.000 description 1
- MFEILWXBDBCWKF-UHFFFAOYSA-N 3-phenylpropanoyl chloride Chemical compound ClC(=O)CCC1=CC=CC=C1 MFEILWXBDBCWKF-UHFFFAOYSA-N 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 229930182579 Cyclotheonamide Natural products 0.000 description 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 1
- 229930182820 D-proline Natural products 0.000 description 1
- 125000000180 D-prolyl group Chemical group N1[C@@H](C(=O)*)CCC1 0.000 description 1
- 238000005361 D2 NMR spectroscopy Methods 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- IVDFJHOHABJVEH-UHFFFAOYSA-N HOCMe2CMe2OH Natural products CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000006219 Matteson homologation reaction Methods 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- WNCIWSMKRPFIJY-UHFFFAOYSA-N Nazumamide A Natural products CCC(C(O)=O)NC(=O)C(C(C)CC)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1=CC(O)=CC=C1O WNCIWSMKRPFIJY-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000531207 Oxera splendida Species 0.000 description 1
- 241000243142 Porifera Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010039286 S 2238 Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241001264631 Theonella sp. Species 0.000 description 1
- JCMMPQNHPDMWBD-UHFFFAOYSA-N Toxadocial A Natural products CCCCCCC(OS(O)(=O)=O)CCCCCCCCCC(OS(O)(=O)=O)CCCCCCCC(C=O)CCCCCC(OS(O)(=O)=O)CCCCCCCCCC(OS(O)(=O)=O)CCCCCC JCMMPQNHPDMWBD-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- AOPRFYAPABFRPU-UHFFFAOYSA-N amino(imino)methanesulfonic acid Chemical compound NC(=N)S(O)(=O)=O AOPRFYAPABFRPU-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical class C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- LVYXMDJSWLEZMP-GQNCZFCYSA-N benzyl (2s)-4-hydroxypyrrolidine-2-carboxylate;hydrochloride Chemical compound Cl.C1C(O)CN[C@@H]1C(=O)OCC1=CC=CC=C1 LVYXMDJSWLEZMP-GQNCZFCYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000003152 bradykinin antagonist Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- FUGIIBWTNARRSF-UHFFFAOYSA-N decane-5,6-diol Chemical compound CCCCC(O)C(O)CCCC FUGIIBWTNARRSF-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 150000002012 dioxanes Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- JPUTTYRVDANTBN-UHFFFAOYSA-N ethyl methanimidate;hydrochloride Chemical compound Cl.CCOC=N JPUTTYRVDANTBN-UHFFFAOYSA-N 0.000 description 1
- XSXLCQLOFRENHC-UHFFFAOYSA-N ethyl n-benzylcarbamate Chemical compound CCOC(=O)NCC1=CC=CC=C1 XSXLCQLOFRENHC-UHFFFAOYSA-N 0.000 description 1
- CUICPJOPYVMUPK-UHFFFAOYSA-N ethyl n-tert-butylcarbamate Chemical compound CCOC(=O)NC(C)(C)C CUICPJOPYVMUPK-UHFFFAOYSA-N 0.000 description 1
- 230000006624 extrinsic pathway Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000006623 intrinsic pathway Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- KIHQEVXNQJYINH-WHFBIAKZSA-N methyl (2s,4s)-4-chloropyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1C[C@H](Cl)CN1 KIHQEVXNQJYINH-WHFBIAKZSA-N 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- XXTWZTPVNIYSJZ-DEOSSOPVSA-N n-[(2s)-3-(4-carbamimidoylphenyl)-1-oxo-1-piperidin-1-ylpropan-2-yl]-2-(naphthalen-2-ylsulfonylamino)acetamide Chemical compound C1=CC(C(=N)N)=CC=C1C[C@@H](C(=O)N1CCCCC1)NC(=O)CNS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 XXTWZTPVNIYSJZ-DEOSSOPVSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 108010068110 nazumamide A Proteins 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- TZLVRPLSVNESQC-UHFFFAOYSA-N potassium azide Chemical compound [K+].[N-]=[N+]=[N-] TZLVRPLSVNESQC-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- ZJLMKPKYJBQJNH-UHFFFAOYSA-N propane-1,3-dithiol Chemical compound SCCCS ZJLMKPKYJBQJNH-UHFFFAOYSA-N 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003441 thioacyl group Chemical group 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- This invention relates to the discovery of novel and useful ⁇ -amino acid analogs, and the pharmaceutically acceptable salts or prodrugs thereof, as inhibitors of thrombin.
- These compounds contain a disubstituted- pyrrolidine ring conjugated to an ⁇ -amino acid functionalized with an electrophilic group such as boronic acids and their esters, ⁇ -perhaloketones and aldehydes.
- Thrombin plays several critical roles in hemostasis, the normal physiological process by which bleeding from an injured blood vessel is arrested. Thrombin cleaves soluble fibrinogen to form insoluble fibrin in the. last proteolytic step of both the extrinsic and intrinsic pathways of the coagulation cascade. Fibrin may be further insolubilized through crosslinking by the thrombin-activated enzyme, factor Xllla. In addition, thrombin-induced activation of platelets leads to their aggregation and the secretion of additional factors that further accelerate creation of a hemostatic plug. Thrombin also potentiates its own production by the activation of factors V and VIII.
- thrombin inhibitors A number of naturally occurring thrombin inhibitors have been isolated. These include the marine sponge natural products Theonella sp . occidentalamide A, a linear tetrapeptide reported by Fusetani et al . , Tetrahedron Let t . 32, 7073-4 (1991); Theonel la sp . cyclotheonamides A and B reported by Fusenati et al., J. Am . Chem . Soc .
- Hirudin a 65 amino acid polypeptide, is responsible for the anticoagulant activity of the medicinal leech, Hirudo medi cinalis .
- Peptide analogs of thrombin substrates and reaction intermediates also inhibit thrombin.
- these include the tripeptide aldehyde (D) -Phe-Pro-Arg-H, disclosed by Bajusz et al . , Int . J. Peptide Protein Res . 12, 217-221 (1978) ; a chloromethyl ketone analog (Ac- (D) -Phe-Pro-ArgCH2Cl, disclosed by Kettner and Shaw, Thromb . Res . 14, 969-73 (1979); polyfluorinated analogs such as (D)-Phe-Pro-Arg-CF2 ⁇ CF3 disclosed by Kolb et al . , AU-B-52881/86; Neises and Ganzhorn, European Patent Application EP 503 203 Al;
- Representative examples of these compounds include t-butyloxycarbonyl- (D)-trimethylsilylalanine-Pro- boroArg-pinanediol, disclosed in Metternich, European Patent Application EP 471 651 A2; Ac-(D)-3- napthylalanine-Pro-boroArg pinanediol ester, disclosed in Kakkar et al., PCT Application WO 92/07869; N- ( t- butyloxycarbonyl) - (D)-phenylglycyl- (L)-prolyl- (L)- arginine aldehyde, disclosed in Gesellchen and Shuman, European Patent Application EP 0 479 489 A2 and J. Med .
- thrombin inhibitors many of which incorporate an arginine or arginine mimic, have also been disclosed. These include arylsulfonylarginine amides such as ( 2R, 4J) -1- [N 2 - (3-ethyl-l, 2, 3, 4- tetrahydro-8-quinolinesulfonyl) -(L)-arginyl]-4-methy1-2- piperidinecarboxylate, disclosed by Okamoto et al . , U.S. Patent No. 4,258,192; Okamoto et al . , Biochem . Biophys . Res . Commun . 101, 440-446 (1981); Kikumoto et al .
- arylsulfonylarginine amides such as ( 2R, 4J) -1- [N 2 - (3-ethyl-l, 2, 3, 4- tetrahydro-8-quinolinesulfonyl) -(L)-
- amidinophenylalanine derivatives such as (2-naphthylsulfonylglycyl) -4- amidino-phenylalanyl piperidine disclosed in Stuber and Dickneite, European Patent Application EP 508 220; amino phenylalanine derivatives, disclosed in Okamoto et al . , U.S. Patent No.
- Isoquinolinyl guanidino benzoate derivatives disclosed by Takeshita et al., European Patent Application EP 435 235 Al; and 2-[3-(4- amidinophenyl) Jpropionic acid derivatives, disclosed by Mack et al . , PCT Application WO 93/01208 also act as thrombin inhibitors.
- thrombin inhibitors contain a 5-membered pyrrolidine ring.
- the pyrrolidine ring is incorporated into the inhibitor as an integral component of the amino acid proline, a 2- substituted pyrrolidine, which in turn is bonded to the remaining atoms of the inhibitor via amide linkages. None of the cited references describe or suggest the new thrombin-inhibiting compounds of the present invention.
- the novel compounds described in the present invention are substituted at the 4-position of the pyrrolidine ring.
- R 3 and R 10 are independently selected at each occurrence from the group consisting of: a) hydrogen, b) halogen,' c) - (CR 6 R 7 ) t W(CR 8 R 9 ) u -R 9 , d) (CR 6 R 7 ) t W(CR 8 R 9 ) u -aryl, e) (CR 6 R 7 ) t W(CR 8 R 9 ) u -heteroaryl, f) (CR 6 R 7 ) t W (CR 8 R 9 ) u -heterocycle, g ) (CR 6 R 7 ) t W(CR 8 R 9 ) u -adamantyl, h) (CR 6 R 7 ) t W(CR 8 R 9 ) u (C 5 -C 7 ) cycloalkyl, i)
- R 3 and R 10 when taken together form a ring such as : a) - (CR 6 R 7 ) t (CR 8 R 9 ) U -W- (CR 8 R 9 ) u (CR 6 R 7 ) t ; b) -(CR 6 R 7 ) t W(CR 8 R 9 ) u -aryl-(CR 8 R 9 ) u W(CR 6 R 7 ) t -; c) - (CR 6 R 7 ) t W(CR 8 R 9 ) u -heteroaryl- (CR 8 R 9 ) U W(CR 6 R 7 ) t -; d) -(CR 6 R 7 ) t W(CR 8 R 9 ) u -heterocycle-(CR 8 R 9 ) u W(CR 6 R 7 ) t -; e) - (CR 6 R 7 ) t (CR 8 R 9 ) u -W- (CR 8 R 9 )
- R 4 and R 5 are independently selected at each occurrence from the group consisting of: a) hydrogen, b) C3 . -C4 alkyl, c) C1-C4 alkoxy, d) C5-C 7 cycloalkyl, e) phenyl, f) benzyl;
- R 11 is a) hydrogen, b) C 1 -C 4 alkyl, c) C 1 -C 4 thioalkyl, d) - (CR 6 R ) t W(CR 8 R 9 ) u -aryl, e) - (CR 6 R 7 ) t W(CR 8 R 9 ) u -heteroaryl, f ) - (CR 6 R 7 ) t W(CR 8 R 9 ) u -heterocycle; g) - (CR 6 R 7 ) t W(CR 8 R 9 ) u -R 9 ;
- Y 1 and Y 2 are a) -OH, b) -F,
- Y 1 and Y 2 form: e) a cyclic boron ester where said chain or ring contains from 2 to 20 carbon atoms and, optionally, 1-3 heteroatoms which can be N, S, or O, f) a cyclic boron amide where said chain or ring contains from 2 to 20 carbon atoms and, optionally, 1-3 heteroatoms which can be N, S, or 0, g) a cyclic boron amide-ester where said chain or ring contains from 2 to 20 carbon atoms and, optionally, 1-3 heteroatoms which can be N, S, or 0;
- n can be 0 to 4.
- 5 n can be 0 to 4.
- p can be 0 to 2
- 0 q can be 0 to 4.
- r, s, t, u, and v are independently selected at each occurrence from 0 to 6,
- 5 w and x are independently selected at each occurence from 0 to 4.
- Preferred compounds of formula (I) are those compounds wherein :
- R 1 is (C3-C 4 alkyl) ;
- R 2 is hydrogen or C 1 -C 4 alkyl.
- More prefe rred compounds of f ormu la ( I ) are compounds of formula ( Ia ) :
- R 1 is (C 3 -C 4 alkyl) ;
- R 2 is hydrogen or C 1 -C 4 alkyl
- R 3 and R 10 are independently selected at each occ rrence from the group consisting of: a) hydrogen, b) halogen, c) - (CR 6 R 7 ) t W(CR 8 R 9 ) u -R 9 d) - (CR 6 R 7 ) t W(CR 8 R 9 ) u -aryl e) - (CR 6 R 7 ) t W(CR 8 R 9 ) u -heteroaryl;
- R 4 and R 5 are independently selected at each occurrence from the group consisting of: a) hydrogen, b) C 1 -C 4 alkyl,
- Y 1 and Y 2 are a) -OH, b) -F, c) -NR R 5 -, d) -Ci-C ⁇ alkoxy, or; when taken together Y 1 and Y 2 form: e) a cyclic boron ester where said chain or ring contains from 2 to 20 carbon atoms and, optionally, 1-3 heteroatoms which can be N, S, or 0, f) a cyclic boron amide where said chain or ring contains from 2 to 20 carbon atoms and, optionally, 1-3 heteroatoms which can be N, S, or 0, g) a cyclic boron amide-ester where said chain or ring contains from 2 to 20 carbon atoms and, optionally, 1-3 heteroatoms which can be N, S, or 0;
- p can be 0 or 2;
- r can be independently selected at each occurrence from 0 to 3;
- s can be independently selected at each occurrence from 0 to 3;
- t can be independently selected at each occurrence from 0 to 2;
- u can be independently selected at each occurrence from
- w can be independently selected at each occurrence from
- x can be independently selected at each occurrence from 0 to 3; with the following provisos: (a) when V is (CH 2 ) X , x cannot be 0 when R 3 is hydrogen;
- R 1 is (C 3 -C4 alkyl) ;
- X is from the ' group consisting of
- R 2 is hydrogen or C 1 -C 4 alkyl
- R 3 is independently selected from the group consisting of: benzyl, phenyl, phenethyl, (3-phenyl)prop-1-yl, (2- methyl-1-phenyl)prop-2-yl, (2-methy1-2-phenyl)prop- 1-yl, 1, 1-diphenylmethyl, phenoxymethyl, phenylsulfonylmethyl, 2- ( ⁇ n-fluorophenyl) ethyl, 2- (3-pyridyl) ethyl, (/n-aminophenyl)methyl, (m- methylphenyl) methyl, (p-methylphenyl) methyl, 1- naphthylmethyl;
- .10 is independently selected from the group consisting of: methyl, t-butoxy, benzyloxy, phenethyl, benzyl, phenoxymethyl, isopropyl, isoamyl, N-methyl -N-t- butoxycarbonylaminomethyl, iV-methylaminomethyl, (m- methyl) phenethyl, (m-fluoro) phenoxymethyl, (m- methyl) phenoxymethyl, (3-pyridyl) ethyl
- R 11 is hydrogen
- Y 1 and Y 2 are a) -OH, b) -F, c) - ⁇ R R 5 -, d) -Ci-Ce alkoxy, or; when taken together Y 1 and Y 2 form: e) a cyclic boron ester where said chain or ring contains from 2 to 20 carbcn atoms and, optionally, 1-3 heteroatoms which can be N, S, or 0, f) a cyclic boron amide where said chain or ring contains from 2 to 20 carbon atoms and, optionally, 1-3 heteroatoms which can be N, S, or 0, g) a cyclic boron amide-ester where said chain or ring contains from 2 to 20 carbon atoms and, optionally, 1-3 heteroatoms which can be N, S, or 0;
- Specifically preferred compounds of formula (I) are those compounds of formula (lb) :
- (D) indicates the amino acid is in the (D)-configuration .
- “D, " indicates the amino acid is present as a mixture of the (D)- and the (L)-configuration.
- the prefix "bore” indicates amino acid residues where the carboxyl is replaced by a boronic acid or a boronic acid ester. For example, if R 1 is isopropyl and Y- and Y- are OH, the C- terminal residue is abbreviated "boroVal-OH” or "jboroValine” where "-OH” indicates the boronic acid is in the form of the free acid.
- pinanediol boronic acid ester and the pinacol boronic acid ester are abbreviated "-C10H16" and "-C6H12", respectively.
- Examples of other useful diols for esterification with the boronic acids are 1, 2-ethanediol, 1, 3-propanediol, 1, 2-propanediol, 2, 3-butanediol, 1,2- diisopropylethanediol, 5, 6-decanediol, and 1,2- dicyclohexylethanediol .
- CBZ or Z benzyloxycarbonyl
- BSA benzenesulfonic acid
- THF tetrahydrofuran
- Boc- t- butoxycarbonyl-
- Ac- acetyl
- pNA p-nitroaniline
- DMAP 4-dimethylaminopyridine
- HOBT 1-hydroxybenzotriazole and hydrate thereof
- DCC 1, 3-dicyclohexylcarbodimide
- Tris Tris (hydrqxymethyl)aminomethane
- MS mass spectrometry
- FAB/MS fast atom bombardment mass spectrometry.
- HRMS are low and high resolutior. mass spectrometry, respectively, using ammonia (NH 3 -CI) or methane (CH 4 -CI) as an ion source.
- the compounds of the present invention contain one or more chiral centers and that these stereoisomers may possess distinct physical and biological properties.
- the present invention comprises all of the stereoisomers or mixtures thereof. If the pure enantiomers or diasteromers are desired, they may be prepared using starting materials with the appropriate stereochemistry, or may be separated from mixtures of undesired stereoisomers by standard techniques, including chiral chromatography and recrystallization of diastereomeric salts.
- any variable for example, R- through R ⁇ -0, m, n, W, Z, etc.
- its definition on each occurrence is independent of its definition at every -other occurrence.
- R 3 is - (CR 6 R 7 ) t -W- (CR 8 R 9 ) u -aryl, and u is 0 it is the same as : - (CR 6 R ) t -W-aryl .
- R 6 and R 7 are taken to for a double bond, and R 8 and R 9 taken to be a triple bond would be:
- amine-blocking group or "amine- protecting group” as used herein, refers to various acyl, thioacyl, alkyl, sulfonyl, phosphoryl, and phosphinyl groups comprised of 1 to 20 carbon atoms. Substituents on these groups may include either alkyl, aryl and alkaryl which may contain the heteroatoms, 0, S, and N as a substituent or as an inchain component. A number of amine-blocking groups are recognized by those skilled in the art of organic synthesis.
- suitable groups include formyl, acetyl, benzoyl, trifluoroacetyl, and methoxysuccinyl; aromatic urethane protecting groups, such as benzyloxycarbonyl; and aliphatic urethane protecting groups, such as t- butoxycarbonyl (also referred to as t-butyloxycarbonyl) or adamantyloxycarbonyl .
- aromatic urethane protecting groups such as benzyloxycarbonyl
- aliphatic urethane protecting groups such as t- butoxycarbonyl (also referred to as t-butyloxycarbonyl) or adamantyloxycarbonyl .
- amino acid residues refers to natural or unnatural amino acid of either (D)- or (L)- configuration. Natural amino acids residues are Ala, Arg, Asn, Asp, Cys, Gin, Glu, Gly, His, lie, Leu, Lys,
- amino acid residue also refers to various amino acids where sidechain functional groups are coupled with appropriate protecting groups known to those skilled in the art.
- the Peptides Vol 3, 3-88 (1981) describes numerous suitable protecting groups and is incorporated herein by reference for that purpose.
- alkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms;
- alkoxy represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge;
- cycloalkyl is intended to include saturated ring groups, including mono-,bi- and polycyclic ring systems, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl and cyclooctyl, and so forth.
- Alkenyl is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl, and the like.
- Halo or “halogen” as used herein refers to fluoro, chloro, bromo, and iodo.
- aryl is defined as phenyl, fluorenyl, biphenyl and naphthyl, which may be unsubstituted or include optional substitution with one to three substituents .
- heteroaryl is meant to include 5-, 6- or 10-rnernbered mono- or bicyclic aromatic rings which can optionally contain from 1 to 3 heteroatoms selected from the group consisting of 0, N, and S; said ring(s) may be unsubstituted or include optional substitution with one to three substituents.
- heteroaryl include the following: 2-, or 5-, or 4-pyridyl; 2-or 3-furyl; 2- or 3-benzofuranyl; 2-, or 3-thiophenyl; 2- or 3- benzo [b]thiophenyl; 2-, or 3-, or 4-quinolinyl; 1-, or 3-, or 4-isoquinolinyl; 2- or 3-pyrrolyl; 1- or 2- or 3- indolyl; 2-, or 4-, or 5-oxazolyl; 2-benzoxazolyl ; 2- or 4- or 5-imidazolyl; 1- or 2- benzimidazolyl; 2- or 4- or 5-thiazolyl; 2-benzothiazolyl; 3- or 4- or 5- isoxazolyl; 3- or 4- or 5-pyrazolyl; 3- or 4- or 5- isothiazolyl; 3- or 4-pyridazinyl; 2- or 4- or 5- pyrimidinyl; 2-pyrazinyl; 2-triazinyl; 3-
- 2c cinnolinyl 1-phthalazinyl; 2- or 4-quinazolinyl; or 2- quinoxalinyl ring.
- Particularly preferred are 2-, 3-, or 4-pyridyl; 2-, or 3-furyl; 2-, or 3-thiophenyl; 2-, 3-, or 4-quinolinyl; or 1-, 3-, or 4-isoquinolinyl.
- heterocycle is meant to include 5-, 6- or 10-membered mono- or bicyclic rings which can optionally contain from 1 to 3 heteroatoms selected from the group consisting of 0, N, and S; said ring(s) may be unsubstituted or include optional substitution with one to three substituents. Included in the definition of the group heterocycle, but not limited to, 2- or 3- pyrrolidinyl, a 2-, 3-, or 4-piperidinyl, or a 1-, 3-, or 4-tetrahdroisoquinolinyl, 1-, 2-, or 4- tetrahydroquinolinyl, 2- or 3-tetrahydrofuranyl, 2- or
- 3-tetrahydrothiophene 1-, 2-, 3-, or 4-piperazinyl, and 1-, 2-, 3-, or 4-morpholino.
- Particularly preferred are 1-, 3-, or 4-tetrahdroisoquinolinyl, 2- or 3- pyrrolidinyl, and 2-, 3- or 4-piperidinyl.
- stable compound or “stable structure” is meant herein a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture and formulation into an efficacious therapeutic agent .
- pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound of formula (I) is modified by making acid or base salts of the compound of formula (I) .
- Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids and the like .
- compositions of the compounds of the invention can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, methanol, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed. , Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
- Prodrugs are considered to be any covalently bonded carriers which release the active parent drug according to formula (I) in vi vo when such prodrug is administered to a mammalian subject .
- Prodrugs of the compounds of formula (I) are prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compounds.
- Prodrugs include compounds of formula (I) wherein hydroxy, amine, or sulfhydryl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino, or sulfhydryl group, respectively.
- Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of formula (I) .
- (L) -4-hydroxyproline benzyl ester hydrochloride which is commercially available, or any other suitably protected hydroxyproline, can be treated with a trialkylamine base, typically 4-methylmorpholine, and an acid chloride (R 10 C C1) to afford acylation product (II) selectively.
- the hydroxyl group can be converted to a corresponding ester by treatment with a second acid chloride (R 3 COCl) in the presence of a trialkylamine or heterocyclic amine base, such as pyridine, and ' a suitable catalyst, such as but not limited to DMAP to generate (III) .
- the carboxylic acid of the proline moiety can be liberated by hydrogenation using conditions reported by Hartney and Simonoff, Org . React . VII, 263 (1953) wherein an alcohol solution of the compound (III) may be affected under an atmosphere of hydrogen gas using a suitable catalyst, preferably platinum or palladium on carbon catalyst, to provide (IV) .
- a suitable catalyst preferably platinum or palladium on carbon catalyst
- the DCC/DMAP esterification procedure reported by Hassner, and Alexanian, Tetrahedron Let t . 19, 4475 (1978) has proved useful for performing the second acylation reaction.
- ester other than benzyl which might be removed hydrolytically or photilytically, such as photlytic deprotection.
- a methyl ester of (II) treatment of an alcoholic solution of the compound with a solution of sodium hydroxide so as to deliver 1 equivalent amount of NaOH followed by acidification should provide the carboxylic acid.
- N-acyl-4- (alkoxy)proline intermediates can prepared as shown in Scheme 2.
- the hydroxyl function of an N-protected 4-hydroxyproline (V) can be alkylated according to the method of Smith et al., JV Med . Chem . 31, 875 (1988), by treatment with an alkali metal hydride, such as but not limited to sodium hydride and an alkyl halide (R 3 X) to give (VI) .
- an alkali metal hydride such as but not limited to sodium hydride and an alkyl halide (R 3 X) to give (VI) .
- benzyl urethane is also viable where hydrogenation over palladium catalyst deliveres the free amine (VII) .
- Acydlation by one of the methods discussed previously can provide (VIII) .
- the 4-amino and 4-mercaptoproline intermediates useful for the synthesis of compounds of the formula (I), wherein V is S, NH or derivatives thereof, can be prepared according to Scheme 3.
- the hydroxyproline ester (IX) wherein the amine is protected as the BOC or CBZ, can be reacted with carbon tetrachloride/ triphenylphosphine according to the method of Webb and Eigenbrot, J. Org . Chem .
- the chloride- (X) with inversion of stereochemistry.
- the chloride can be displaced by a sulfur nucleophile, again with inversion of sterochemistry in a manner similar to that reported by Smith et al . (1988) to provide the displacement product (Xllb) , sulfur-containing prolines.
- the chloride can be displaced by sodium azide, which is reduced to the primary amine and converted by reductive amination to provide the displacement products (Xlla), nitrogen-containing prolines.
- the R 3 group in (XII) used in the displacement reaction need not be the ultimate R 3 of formula (I); methods for their removal are well known to those skilled in the art of organic synthesis . Methods for the attachment cf preferred R 3 are described herein.
- thrombin inhibitors of the present invention requires the coupling of either of the aforementioned intermediates, (IV), (VIII), or (XII) with a boron-containing fragment followed by manipulation of the pendant functionalities, as shown in Scheme 4.
- jborolysine-containing thrombin inhibitors begins with the coupling of amine hydrochloride (XIII) , disclosed by Kettner and Shenvi U.S. Patent No. 5.187.147, to provide amide (XIV) .
- XIII amine hydrochloride
- One method calls for the combination of (XIII) and the acid chloride derived from (IV), (VIII) or (XII) in the presence of an amine base, such as but not limited to pyridine.
- the mixed anhydride method which involves mixing the acid to be coupled with an alkylchloroformate and an tertiary amine base, such as, but not limited to, i-butyl chloroformate and 4-methylmorpholine, followed by addition of the amine discussed previously, to prepare (XIV) from (IV), (VIII) or (XII) ; additionally the DCC/HOBT method may be used to access amines XIV and/or XII Conversion of the bromide to the X group in R 1 of formula (I) can be accomplished by first reaction of bromide (X) with an inorganic azide, such as sodium or potassium azide, in an anhydrous polar aprotic solvent, such as acetone, N, ⁇ -dimethylformamide or methyl sulfoxide at temperatures ranging from ambient to 130°C; typically reaction with sodium azide in N,JV- dimethylforma ide at 65-70 °C for several hours provides (XV)
- Subsequent reduction of the azide function to the amine (XVI) is effected by catalytic hydrogenation of the azide in a solvent, such as an alcohol or ethyl acetate using a suitable transition metal catalyst under an atmosphere of hydrogen gas.
- Reduction of the azide (XX) in the presence of sulfur-containing prolines (XV, where V is S) can be done according to the method of Knowles et al . , Tetrahedron Lett . , p. 3663 (1978) to provide the amines (XXI) .
- a variety of alternative methods can be found in the monograph by Hudlicky, Reductions In ' Organi c Synthesis, John Wiley and Sons, pp. 134 (1984) .
- the amine (XVI) can be isolated as the free base or a salt, typically, but not exclusively hydrochloride or benzenesulfonate; other salts which impart improved physical properties may be preferred.
- guanidinium analogs can be prepared in a similar manner starting from amine hydrochloride (XVIII) .
- Amide bond formation using one of the methods previously described provides (XIX) , which can be converted to the azide (XX) by nucleophilic displacement of the bromide. Reduction of the azide using conditions already described can provide the amine (XXI) .
- Preparation of formamidine (XXII) can be accomplished by reaction of amine (XXI) with ethyl formimidate hydrochloride in the presence of DMAP according to the method of Ohme and Schmitz, Angew, Chem mt . Ed 6,566 (1967) .
- the organic layer was washed with saturated aqueous sodium bicarbonate (NaHC0 3 , 1 30 mL) , water (H 2 0, 1 x 30 mL) , saturated aqueous sodium chloride (NaCl, 1 >: 30 mL) , dried over sodium sulfate (Na 2 S0 4 ) and concentrated 5 under reduced pressure.
- the resulting oil (1.94 g, l l yield) solidified on standing at room temperature.
- Part B To a solution of the product from Part A (370 mg, 1.41 mmol) and pyridine (0.17 mL, 2.10 mmol) in CH 2 C1 2 (14 mL) at 0 °C was added 3-phenylpropionyl
- Part C A solution of the product from Part E (340 mg, 0.86 mmol) together with palladium on charcoal (50 mg) in methanol (MeOH, 9 mL) was stirred under hydrogen (1 5 at ) for 2 hours. The reaction mixture was filtered through a pad of Celite with additional MeOH (ca. 10 mL) and the filtrate was concentrated under reduced pressure to give (4.R) -N-acetyl-4- (3-phenylpropionyl) oxy- (L)- proline (245 mg) as a foam in 93% yield.
- Part D To a solution of the product from Part C (240 mg, 0.79 mmol) and 4-methylmorpholine (0.26 mL, 2.36 mmol) in tetrahydrofuran (THF, 6 mL) at -20 °C was added i-butyl chloroformate (0.11 mL, 0.87 mmol) after which the reaction mixture was stirred for 2 minutes.
- Part E A mixture of the product from Part D (470 mg, 0.75 mmol) and sodium azide (Na 3 , 97 mg, 1.50 mmol) in DMF (8 mL) was heated at 65-70 °C for 4 hours. The mixture was poured into EtOAc (ca. 75 mL) . and washed with H 2 0 (3 x -20 mL) , sat. aq.
- Part F A solution of the product from Part E (388 mg, 0.65 mmol) in MeOH (7 mL) together with palladium hydroxide on charcoal (35 mg) was stirred under hydrogen (1 atm) for 3 hours. The reaction mixture was filtered through a pad of Celite with additional MeOH (ca. 10 mL) and the filtrate was concentrated under reduced pressure to give 320 mg of the title compound as a foam in 86' ⁇ yield.
- Example 303 To a mixture of Example 303 (1.95 g, 2.52 mmol) in H 2 0 (10 mL) , Et 2 0 (15 mL) , and sufficient MeOH (ca. 1.5 mL) to maintain a clear, biphasic system was added phenylboric acid (1.54 g, 12.6 mmol) . The mixture was stirred for 14 hours, the layers were separated and the aqueous phase was extracted with Et 0 (5 x 20 mL) . The aqueous layer was concentrated under reduced pressure to give the title compound (1.20 g) as an amorphous powder in 75% yield. LRMS 482 (M+H), 464 (base); HRMS Calcd for C 28 H 39 BN 3 0 5 (ethylene gycol ester) : 508.2983. Found:
- Part A The commercially available starting material, (4.R) -N-BOC-4-hydroxy- (L)-proline methyl ester was dissolved in CH C1 2 (140 mL) and carbon tetrachloride (140 mL) and triphenylphosphine (42.56 g, 162.2 mmol) was added. The mixture was allowed to stir for 2 hours, ethanol (15 mL) was added and stirring was continued for an additional 16 hours. The mixture was concentrated under reduced pressure to 100 mL, cooled to -20 °C and Et 2 0 (200 mL) was added. The resulting precipitate was suction filtered ' and washed with Et 0.
- Part B A solution of the product from Part A (17.03 g, 64.5 mmol) in trifluoroacetic acid (20 mL) and CH 2 C1 2 (20 mL) was stirred 18 hours. The reaction mixture was concentrated under reduced pressure to give (4S)-4- chloro-(L)-proline methyl ester (18.05 g) as an oil in quanitative yield.
- -H NMR 300 MHz, CDCI 3 ) ⁇ 4.75 (comp,
- Part C A solution of the product from Part B (30.28 g, 109 mmol) in CH 2 C1 2 (50 mL) was cooled to 0 °C and E 3 N (45.6 mL, 327 mmol) followed by hydrocinnamoyl chloride (17.8 mL, 120 mmol) were added slowly in order to maintain an internal temperature less than 10 °C . After stirring six hours, H 0 (50 mL) was added to the reaction mixture. The resulting solution was extracted with CH 2 C1 2 (3 x 50 mL) .
- Part D EtOH (50 mL) was cooled to 0 °C and sodium (0.78 g, 33.8 mmol) was added. After the hydrogen evolution ceased, thiophenol (3.72 g, 33.8 mmol) was added and the reaction mixture stirred for 15 minutes at 0 °C, and the product from Part C (5 g, 16.9 mmol) was added. The stirring was continued for an additional 16 hours at room temperature. The mixture was concentrated under reduced pressure, diluted with water (20 mL) and acidified with IN HCI to pH . The aqueous solution was extracted with EtOAc (3 x 30 mL) , the organics dried with Na 2 S0 4 and concentrated under reduced pressure.
- Part E Using the method described above for the preparation of Example 78, Part D, ( 1R) -5-bromo- [ (4R) -N- 0 (3-phenylpropionyl)-4- (phenyl)thio- (L)- prolyl]aminopentane-l-boronic acid, (+) -pinanediol ester was isolated (2.43 g) as an oil in 85% yield. LRMS 681.2 683.2 (M+H, base) .
- Part F Using the method described above for Example 5 78, Part E, the intermediate ( 1R) -5-azido- [ (4.R) -N- (3- phenylpropionyl) -4- (phenyl) thio- ( )-prolyl] aminopentane- 1-boronic acid, (+) -pinanediol ester was isolated (2.42 g) as an oil in quantitative yield.
- Part G A solution of the product from Part F (2.42 g, C 3.76 mmol) in 1, 3-propanedithiol (1.62 g, 15 mmol), triethylamine (1.52 g, 15 mmol) and methanol (20 mL) was stirred at 50 °C for 24 hours. The reaction mixture was concentrated under reduce pressure and purified by flash chromatography through florosil, eluting with 1:9 5 MeOH-CH Cl 2 . The concentrated residue was dissolved in diethyl ether (10 mL) , acidified with 1 equivalent of IN HCI in Et 2 0 and concentrated to give the title compound
- Part A A solution of the commercially available starting material, (4.R) -N-BOC-4- (benzyl) oxy- ( )-proline, previously reported by Smith et al., J. Med . Chem . 31, 875 (1988); (2.11 g, 6.57 mmol), in CH 2 C1 2 (27 mL) was treated with anhydrous hydrogen chloride in dioxanes (4 M, 6.60 mL) . The reaction mixture was stirred for 18 hours, during which time a white precipitate formed. The reaction was diluted with diethyl ether (Et 2 0, ca .
- Part B A suspension of the product from Part A (1.5C g, 5.83 mmol) in CH 2 C1 2 (58 mL) at 0 °C was treated with
- Part C Using the method described above for the preparation of Example 78, Part D, (1R) -5-bromo- [ ( R) -N- (3-phenylpropionyl) -4- (benzyl) oxy- (L)- prolyl]aminopentane-1-boronic acid (+) -pinanediol ester was isolated (2.80 g) as an oil in 90% yield. LRMS 679, 681 (M+H, base) .
- Part E A solution of product from Part D (2.24 g, 3.50 mmol) in ' MeOH (35 mL) together with palladium on charcoal (225 mg) was stirred under hydrogen (1 atm) for 1 hour. The reaction mixture was filtered through a pad of Celite with additional MeOH (ca. 30 mL) and the filtrate was concentrated under reduced pressure to give a foam which contained a small amount of unreacted azide. This material was resubjected to the hydrogenation conditions described above to afford the title compound (2.00 g) as a white foam in 93% yield. LRMS 616 (M+H, base) .
- Example 303 A solution of Example 303 (2.00 g, 3.25 mmol) in methanol (25 mL) was treated with a solution of benzenesulfonic acid (0.514 g, 3.25 mmol) in methanol (8 mL) . The mixture was allowed to stand at room temperature for 15 minutes and concentrated under reduced pressure to give a foam. The residue was washed with Et 2 0 (2 x 25 mL) , which was decanted, then dissolved in EtOAc (ca. 20 mL) and triturated with Et 2 0
- Part A A mixture of the product from Example 302, Part C (3.00g, 10.1 mmol) and NaN 3 (3.30 g, 5C.7 mmol) in DMF (15 mL) was heated to 75 °C for 18 hours. Tne reaction mixture was dissolved in H 2 0 (25 mL) . The aqueous solution was extracted with Et 2 0 (3 x 25 mL) , dried with MgS0 4 and concentrated to give (4 ⁇ )-N-(3- phenylpropionyl) -4-azido- (L)-proline methyl ester (2.13 g) as an oil in 83% yield. -H NMR (300 MHz, CDC1 3 ) ⁇
- Part B Using the method described above for the preparation of Example 78, Part F, ( 4 ⁇ ) -N- ( 3- phenylpropionyl) -4-amino-(L)-proline methyl ester was isolated (2.43 g) as an oil in 85% yield. --R ⁇ MR (300 5 MHz, CDCI3) ⁇ 7.24 (comp, 5H) , 4.58 (m, IH) , 3.74
- Part C A_mixture of the product from Part B (1.51 g, 5.46 mmol), benzaldehyde (0.58 g, 5.46 mmol), potassium 0 acetate (0.54 g, 5.46 mmol) and 5% palladium on charcoal (0.21 g) was stirred in MeOH (25 mL) under hydrogen (3 atm) for 5 hours. The reaction mixture was filtered through a pad of Celite with additional MeOH (ca. 10 mL) and the filtrate concentrated under reduced pressure to 5 give (4.R) - ⁇ - (3-phenylpropionyl) -4- (benzyl) amino- (L)- proline methyl ester (2.00 g) as an oil in quantitative yield. 1 H ⁇ MR (300 MHz, CDCI3) ⁇ 7.27 (comp, 10H) , 4.58
- Part D A solution of the product from Part C (2.00 g, 5.46 mmol) methanol (15 mL) and IN sodium hydroxide (9 mL) was stirred for 24 hours. The pH of the solution was adjusted to 6 with IN HCI and a white precipitate 5 formed. The solid material was collected by suction filtration to give (4R) - ⁇ - (3-phenylpropionyl) -4- (benzyl) amino-( )-proline (1.31 g) as a white powder in 68% yield. LRMS 353.2 (M+H, base) .
- Part E Using the method described above for the 0 preparation of Example 78, Part D, ( 1R) -5-bromo- [ (4J ) - ⁇ - (3-phenylpropionyl) -4- (benzyl) amino- (L)- prolyl]aminopen v tane-l-boronic acid, (+) -pinanediol ester was isolated (0.71 g) as an oil in 49% yield. LRMS 678.3 680.3 (M+H, base) .
- Part F Using the method described above for Example 78, Part E, the intermediate (li?) -5-azido- [ (4i?) -N- (3- phenylpropionyl) -4- (benzyl) amino- (L)-prolyl] aminopentane- 1-boronic acid, (+)-pinanediol ester was isolated (0.45 g) as an oil in 67% yield.
- Part G A solution of the product from Part F (0.45 g, 0.70 mmol) in MeOH (5 mL) together with 20% palladium hydroxide on charcoal (0.04 g) was stirred under hydrogen (1 atm) for 4 hours.
- the reaction mixture was filtered through a pad of Celite with EtOAc (ca. 10 L) .
- the filtrate was concentrated under reduced pressure and purified by flash chromatography through florosil, eluting with 1:9 MeOH-CH 2 Cl 2 .
- the concentrated residue was dissolved in Et 0 (10 mL) , acidified with 2 equivalents of IN HCI in Et 0 and concentrated to give the title compound (0.27 g) as a oil in 56% yield.
- Part B A mixture of the product from Part A (365 mg, 0.55 mmol) and thiourea (83 mg, 1.10 mmol) in ethanol (EtOH, 10 mL) was heated at reflux for 16 hours and cooled to room temperature. The reaction was poured into Et 2 0 (ca. 120 mL) and concentrated under reduced
- the compounds of formula (I) are useful as inhibitors of serine proteases and notably human thrombin, plasma allikrein and plas in . Because of their inhibitory action, these compounds are indicated for use in the prevention or treatment of physiological reactions, blood coagulation and inflammation, catalyzed by the aforesaid class of enzymes .
- Inhibition constants were determined by the method described by Kettner et al . in J. Bi ol . Chem . 265, 18289-18297 (1990), herein incorporated by reference.
- thrombin-mediated hydrolysis cf the chromogenic substrate S2238 (Helena Laboratories, Beaumont, TX)- was monitored spectrophotometrically . Addition of an inhibitor to the assay mixture results n decreased absorbance and is indicative of thrombin inhibition.
- Human thrombin (Enzyme Research Laboratories, Inc., South Bend, IN) at a concentration of 0.2 nM in 0.10 M sodium phosphate buffer, pH 7.5, 0.20 M NaCl, and 0.5% polyethylene glycol 6000, was incubated with various substrate concentrations ranging from 0.20 to 0.02 mM. After 25 to 30 minutes of incubation, thrombin activity was assayed by monitoring the rate of increase in absorbance at 405 nm which arises owing to substrate hydrolysis. Inhibition constants were derived from reciprocal plots of the reaction velocity as a function of substrate concentration using the standard method of Lineweaver and Bur .
- Bovine thrombin was obtained from Sigma and diluted to 24 NIH units/mL. Plasma ( 0.2 mL) and buffer (0.05 mL, 0.10 M Tris [hydroxymethyl]-aminomethane hydrochloride, pH 7.4, 0.9% (w/v) sodium chloride, and 2.5 mg/mL bovine serum albumin) containing inhibitor were incubated 3 min at 37 °C in a fibrameter. Reactions were initiated by adding thrombin (0.05 mL) to achieve a final concentration of 4 NIH units/mL.
- the compounds of formula (I) have anti- thrombogenic properties, they may be employed when an anti-thrombogenic agent is indicated, such as for the control of the coagulation of the fibrinolysis system in mammals or they may be added to blood for the purpose of preventing coagulation of the blood due to contact with blood collecting or distribution containers, tubing or apparatus. Generally, these compounds may be administered orally, parenterally or intravenously to a host to obtain an anti-thrombogenic effect.
- the dosage of the active compound depends on the mammalian species, body weight, age, and mode of administration as determined by one skilled in the art.
- the compounds may be administered alone or in combination with pharmaceutical carriers or diluents at a dose of from 0.02 to 15 mg/kg to obtain the anti-thrombogenic effect, and may be given as a single dose or in divided doses or as a sustained release formulation.
- Pharmaceutical carriers or diluents are well known and include sugars, starches and water, which may be used tc make tablets, capsules, injectable solutions or the like which can serve as suitable dosage forms for administration of the compounds of this invention.
- Remington's Pharmaceutical Sciences. A. Osol is a standard reference text which discloses suitable pharmaceutical carriers and dosage forms. The disclosure of this text is hereby incorporated by reference for a more complete teaching of suitable dosage forms "for administration of the compounds of this invention .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13325093A | 1993-10-07 | 1993-10-07 | |
US133250 | 1993-10-07 | ||
US13944393A | 1993-10-20 | 1993-10-20 | |
PCT/US1994/011049 WO1995009859A1 (en) | 1993-10-07 | 1994-10-06 | Boropeptide inhibitors of thrombin which contain a substituted pyrrolidine ring |
US139443 | 1998-08-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0722449A1 true EP0722449A1 (de) | 1996-07-24 |
Family
ID=26831201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94929943A Withdrawn EP0722449A1 (de) | 1993-10-07 | 1994-10-06 | Boropeptid thrombin-inhibitoren, welche einen substituierten pyrrolidinring enthalten |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0722449A1 (de) |
AU (1) | AU7922794A (de) |
CA (1) | CA2174311A1 (de) |
WO (1) | WO1995009859A1 (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5707966A (en) * | 1994-03-04 | 1998-01-13 | Eli Lilly And Company | Antithrombotic agents |
US5885967A (en) * | 1994-03-04 | 1999-03-23 | Eli Lilly And Company | Antithrombotic agents |
US5705487A (en) * | 1994-03-04 | 1998-01-06 | Eli Lilly And Company | Antithrombotic agents |
ZA951618B (en) * | 1994-03-04 | 1996-08-27 | Lilly Co Eli | Antithrombotic agents |
US5726159A (en) * | 1994-03-04 | 1998-03-10 | Eli Lilly And Company | Antithrombotic agents |
US5602101A (en) * | 1994-03-04 | 1997-02-11 | Eli Lilly And Company | Antithrombotic agents |
CA2143533A1 (en) * | 1994-03-04 | 1995-09-05 | Kenneth D. Kurz | Antithrombotic agents |
US5710130A (en) * | 1995-02-27 | 1998-01-20 | Eli Lilly And Company | Antithrombotic agents |
US5914319A (en) * | 1995-02-27 | 1999-06-22 | Eli Lilly And Company | Antithrombotic agents |
AU2001268607A1 (en) | 2000-06-21 | 2002-01-02 | Bristol-Myers Squibb Company | Piperidine amides as modulators of chemokine receptor activity |
KR20050057294A (ko) * | 2002-09-09 | 2005-06-16 | 트라이젠 리미티드 | 보론산 염, 및 혈전증의 치료를 위한 그것의 용도 |
US20050288253A1 (en) | 2002-09-09 | 2005-12-29 | Trigen Limited | Boronic acid salts |
PT2800738T (pt) * | 2012-01-06 | 2020-06-23 | Novartis Ag | Compostos heterocíclicos e métodos para a utilização dos mesmos |
WO2014058538A1 (en) * | 2012-08-27 | 2014-04-17 | Merck Sharp & Dohme Corp. | Substituted pyrrolidine thrombin inhibitors |
WO2017156071A1 (en) | 2016-03-09 | 2017-09-14 | Blade Therapeutics, Inc. | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof |
EP3481835A4 (de) | 2016-07-05 | 2020-02-26 | Blade Therapeutics, Inc. | Calpain-modulatoren und therapeutische verwendungen davon |
CN110023304A (zh) | 2016-09-28 | 2019-07-16 | 布莱德治疗公司 | 钙蛋白酶调节剂及其治疗用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5187157A (en) * | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
GB9017694D0 (en) * | 1990-08-13 | 1990-09-26 | Sandoz Ltd | Improvements in or relating to organic chemistry |
GB9024129D0 (en) * | 1990-11-06 | 1990-12-19 | Thrombosis Research Trust | Inhibitors and substrates of thrombin |
EP0503203A1 (de) * | 1991-03-15 | 1992-09-16 | Merrell Dow Pharmaceuticals Inc. | Neue Thrombin-Inhibitoren |
-
1994
- 1994-10-06 CA CA002174311A patent/CA2174311A1/en not_active Abandoned
- 1994-10-06 WO PCT/US1994/011049 patent/WO1995009859A1/en not_active Application Discontinuation
- 1994-10-06 AU AU79227/94A patent/AU7922794A/en not_active Abandoned
- 1994-10-06 EP EP94929943A patent/EP0722449A1/de not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO9509859A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2174311A1 (en) | 1995-04-13 |
AU7922794A (en) | 1995-05-01 |
WO1995009859A1 (en) | 1995-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU636521B2 (en) | Inhibitors and substrates of thrombin | |
EP1050540B1 (de) | Inhibitoren der Dipeptidyl-Aminopeptidase vom Typ IV | |
US5462928A (en) | Inhibitors of dipeptidyl-aminopeptidase type IV | |
DE3878991T2 (de) | Peptide boronsaeure-hemmungsstoffe von trypsintyp-proteasen. | |
EP0722449A1 (de) | Boropeptid thrombin-inhibitoren, welche einen substituierten pyrrolidinring enthalten | |
EP0145441B1 (de) | Peptide aus alpha-Aminoboronsäuren | |
US6825169B1 (en) | Inhibitors of dipeptidyl-aminopeptidase type IV | |
EP0787010A1 (de) | Amidino- und guanidino-substituierte inhibitoren für trypsin ähnliche enzyme | |
WO1995011689A1 (en) | Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells | |
EP0724446A1 (de) | Elektrophile peptidanaloga als inhibitoren trypsin-aehnlicher enzyme | |
WO1995009858A1 (en) | Dipeptide boronic acid inhibitors of trypsin-like enzymes | |
EP0345359B1 (de) | Hydroxaminsäureabkömmling | |
US5639739A (en) | Imidazole containing aminoboronic acids | |
EP0731788A1 (de) | Prolyl-endopeptidaseinhibitoren | |
US5462964A (en) | Dipeptide boronic acid inhibitors of trypsin-like enzymes | |
AU703854B2 (en) | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | |
AU707059B2 (en) | Serine protease inhibitors | |
WO1994021650A1 (en) | Boronic acid and ester inhibitors of thrombin | |
US6387881B1 (en) | Inhibitors and substrates of thrombin | |
NZ299833A (en) | Treating or preventing thrombosis using azacycloalkanol peptides and pseudopeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19960328 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19971113 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 19980311 |